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Newly Defined ATP-Binding Cassette Subfamily B
Member 5 Positive Dermal Mesenchymal Stem
Cells Promote Healing of Chronic Iron-Overload
Wounds via Secretion of Interleukin-1 Receptor
Antagonist
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ABSTRACT
In this study, we report the beneficial effects of a newly identified dermal cell subpopulation
expressing the ATP-binding cassette subfamily B member 5 (ABCB5) for the therapy of nonhealing
wounds. Local administration of dermal ABCB5+-derived mesenchymal stem cells (MSCs) attenuated
macrophage-dominated inflammation and thereby accelerated healing of full-thickness excisional
wounds in the iron-overload mouse model mimicking the nonhealing state of human venous leg
ulcers. The observed beneficial effects were due to interleukin-1 receptor antagonist (IL-1RA)
secreted by ABCB5+-derived MSCs, which dampened inflammation and shifted the prevalence of
unrestrained proinflammatory M1 macrophages toward repair promoting anti-inflammatory M2
macrophages at the wound site. The beneficial anti-inflammatory effect of IL-1RA released from
ABCB5+-derived MSCs on human wound macrophages was conserved in humanized NOD-scid
IL2rγnull mice. In conclusion, human dermal ABCB5+ cells represent a novel, easily accessible, and
marker-enriched source of MSCs, which holds substantial promise to successfully treat chronic non-
healing wounds in humans. STEM CELLS 2019;37:1057–1074
SIGNIFICANCE STATEMENT
The ATP-binding cassette protein ATP-binding cassette subfamily B member 5 (ABCB5), a single
molecular marker, can be used to isolate dermal cell subpopulation of the skin with multipotent
mesenchymal stromal cell (MSC) characteristics from its endogenous niche. The ABCB5+ MSCs
maintain most of their stemness and mesenchymal marker during large in vitro expansion cul-
tures as well as the capacity for clonal self-renewal and, importantly, promote healing of non-
healing iron-overload wounds in a murine model, which may be exploited as a potential
regenerative therapy for chronic venous leg ulcers in human patients.
INTRODUCTION
Although poorly defined, self-renewing adult plu-
ripotent mesenchymal stem cells (MSCs) reside
within nearly all adult connective tissues, includ-
ing the dermis [1, 2]. Their most important func-
tion is to maintain their niche environment,
a critical requirement to protect their own
stemness and long-term self-renewal capacity
essential for tissue homeostasis, repair, and
organ maintenance [3].
Due to their capacity to engraft and release
wound healing-promoting factors, profound
interest has developed in advanced MSC-based
therapies for patients suffering from acute and
chronic wounds. To date, 1% to 2% of the popu-
lation in developed countries suffer from a non-
healing wound, and the incidence of chronic
wounds is estimated to increase due to the
world-wide increase in elderly, obese, and dia-
betic patients [4]. One major hurdle still hamper-
ing the successful implementation of large-scale
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REGENERATIVE MEDICINE
MSC-based therapies in clinical practice is the lack of a cell sur-
face marker that reliably allows to enrich and expand MSCs for
reproducible paracrine efficacy and potency.
Recently, we showed that ATP-binding cassette subfamily B
member 5 (ABCB5) identifies a novel dermal immunomodula-
tory subpopulation, which in addition expresses MSC markers
and exerts suppressive effects on effector T cells, whereas
enhancing regulatory T cells in vitro and in vivo [5]. ABCB5
belongs to the multiple drug resistant cell membrane-anchored
proteins that are also expressed on limbal stem cells of the
eye where its absence results in blindness [6]. By means of
specific antibodies, we here show that the ABCB5+ dermal
MSC population can reliably be isolated according to GMP
standards and thus holds substantial promise to define a more
homogeneous MSC population for large-scale expansion with
improved efficacy and potency, urgently required for advanced
treatment of chronic wounds.
Although different in etiology, chronic wounds share the
common feature of persistent high numbers of overactivated
proinflammatory M1 macrophages [7, 8] with enhanced release
of tumor necrosis factor alpha (TNFα) and other proinflammatory
cytokines. These proinflammatory cytokines along with proteases
and reactive oxygen species lead to tissue breakdown and the
installment of a senescence program in resident wound site fibro-
blasts, thus perpetuating a nonhealing state of these wounds.
We previously identified iron accumulation in macrophages resid-
ing in chronic venous leg ulcers as a consequence of persistent
extravasation of red blood cells at the wound site due to
increased blood pressure and venous valve insufficiency. Iron
overloaded macrophages in these wounds fail to switch from
their proinflammatory M1 state to anti-inflammatory M2 macro-
phages required for tissue remodeling and restoration [7]. M2
macrophages show a lower inflammatory cytokine release as
opposed to their M1 counterparts and produce growth factors
and metabolites that stimulate tissue repair and wound healing [9].
Conversely, effector molecules like TNFα and interleukin-1 β
(IL-1β), among others released by M1 macrophages, maintain a
vicious cycle of autocrine recruitment and constant activation of
M1 macrophages, thus virtually locking wounds in a nonhealing
state of persistent inflammation [7, 8].
We here specifically addressed the involvement of para-
crine mechanisms used by ABCB5+-derived MSCs to counteract
persisting inflammation and to switch the prevailing M1 mac-
rophages toward tissue repair promoting M2 macrophages, a
prerequisite for healing of chronic wounds.
To exclude any engraftment or cell fusion effects, we pur-
posely used a xenotransplant model with local injection of human
ABCB5+-derived MSCs into chronic wounds of the iron-overload
murine model closely mirroring the major pathogenic aspect of
unrestrained M1 macrophage activation in human chronic
wounds [7]. We have used clinical grade approved ABCB5+ MSC
preparations with documented clonal trilineage differentiation
capacity, enhanced clonal growth, and TNFα suppressing activity
in vitro as valuable predictors for successful treatment of chronic
wounds in vivo. We found that ABCB5+-derived MSCs injected
into iron-overload wounds enhanced release of the paracrine
IL-1 receptor antagonist (IL-1RA) and, indeed, switched the prev-
ailing M1 proinflammatory macrophage phenotype excessively
increased in chronic iron-overload murine wounds to an anti-
inflammatory M2 macrophage promoting overall wound healing.
The causal role of the paracrine release of IL-1RA from injected
ABCB5+-derived MSCs was supported by our findings that injec-
tion of human recombinant IL-1RA accelerated wound healing,
whereas injection of IL-1RA silenced ABCB5+-derived MSCs
did not. Notably, these data are recapitulated in humanized
NOD-scid IL2rγnull (NSG) mice, with a shift from human pro-
inflammatory M1 to anti-inflammatory M2 macrophages further
paving the way for the successful translation of marker-enriched
ABCB5+ MSCs therapies into clinical practice for the long-term
benefit of our patients.
MATERIALS AND METHODS
Study Design
The purpose of this study was to determine whether human
dermal ABCB5+ cells are MSCs and have beneficial effects on
chronic wound healing in cellular therapeutic applications. In vitro,
ABCB5+ MSCs and donor-matched ABCB5− human dermal fibro-
blasts (HDFs) from at least six different donors (Supporting Infor-
mation Table S1: B02-B07) were tested for MSC-characteristic
trilineage differentiation, surface marker expression, clonogenic
growth, self-renewal, and anti-inflammatory effects on activated
macrophages by quantitative measures. In vivo, improvement on
wound healing by anti-inflammatory mechanisms was assessed in
the mouse iron-overload full-thickness excisional wound model
for chronic venous ulcers, characterized by delayed wound clo-
sure, prolonged inflammation, and M1-activated macrophage
abundance [7]. For these animal studies, sample sizes were esti-
mated based on differences in wound closure from our previ-
ous study identifying delayed wound healing in genetically
modified mice [10] in order to reach a significance level of 5%
and a statistical power of 80% by the Welch’s test, with the
inclusion of one additional animal (four wounds) to protect
against deviations from the Gaussian distribution. Key animal
experiments with ABCB5+-derived MSCs and donor-matched
ABCB5− HDF injection were performed 3 times with cells from
three different donors (Supporting Information Table S1: B01,
B13, B14). Repetition experiments for sample collection were
performed with human dermal cells either from the donor with
internal number B01 (Supporting Information Table S1) for
which cell preparation purities (Fig. 2A) and wound closure
data (Fig. 3F, 3G) are shown here or with a phenotypically and
functionally verified pooled sample of cells from six different
donors (Supporting Information Fig. S4 and Table S1). This
pooled dermal ABCB5+-derived MSC preparation was also used
for IL-1RA knockdown and humanized NSG mouse wound clo-
sure experiments. The equal amount of cells derived from inde-
pendent biological samples were analyzed in each quantitative
assay. Microscopic images are representative for six wound
samples per treatment group. Biological samples for analysis
of xenografted ABCB5+-derived MSC persistence by human-
specific beta actin quantitative polymerase chain reaction
(qPCR) on wound sections and enzyme-linked immunosorbent
assay (ELISA) quantification of wound cytokine titers are each
pooled from two independent wounds and for hIL-1RA Western
blot and wound macrophage flow cytometry from four inde-
pendent wounds.
Human Skin Samples
Skin biopsies used for the isolation of ABCB5+ and ABCB− cell frac-
tions in this study measured 1 cm2 and were either taken from
©2019 The Authors. STEM CELLS published by
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young healthy volunteers at the University Clinic of Dermatology
and Allergic Diseases in Ulm or the University Clinic of Gynecology
(skin from healthy females undergoing reduction mammoplasty;
donors B02–B07) after approval by the ethical committee at Ulm
University or directly derived from clients of Ticeba GmbH
(Heidelberg, Germany; donors B01 and B08–B14) according to
the Declaration of Helsinki principles after informed written
consent was obtained. Localization was chosen to avoid isola-
tion of cells from sun-exposed areas of the skin. The variation
in localization (gluteal region, inner upper arm, or behind left
ear) depended on surgical standards and donor preference.
All biopsies were histologically assessed for any pathology. Only
biopsies without pathology were used for immunostaining or for
isolation of ABCB5+ and ABCB− cell fractions. None of the biop-
sies taken failed to yield ABCB5+cells. Anonymized donor data
can be found in Supporting Information Table S1. Expansion of
plastic-adherent dermal cells and ABCB5-based separation modi-
fied from Frank et al. [11] was performed as indicated (please
see Supporting Information Materials and Methods for details).
Cell viability was assessed before in vitro experiments, and no
difference was found between both in the ABCB5+ and ABCB5−
population (>90%). Also, when harvesting ABCB5+ MSCs and the
ABCB5− cell fraction by Accutase for the injection into wounds,
viability is routinely checked by trypan blue exclusion and is
consistently very high (>90%) both in the ABCB5+ and ABCB5−
population.
Before application in in vivo wound-healing experiments,
ABCB5+ cell preparations were tested for their M1 macrophage
suppressing function in a coculture with interferon-γ (IFN-γ)/Lipo-
polysaccharide (LPS)-activated murine bone marrow-derived
macrophages, and the release of TNFα was assessed by a
mouse-specific TNFα ELISA (R&D Systems, Germany; Figs. 3B,
6D; Supporting Information Fig. S4).
Differentiation and Clonogenic Growth Assays
In vitro adipogenic, osteogenic, and chondrogenic differentiation
capacity was examined using commercial differentiation media
(Lonza, Germany) and TGF-β3 (CellSystems, Germany) and proce-
dures according to manufacturer’s descriptions. For adipogenic
differentiation, lipid droplet accumulation was verified by staining
with Oil Red O (Sigma-Aldrich, Germany) and quantified by dye
extraction as described previously [12]. Mineralization of the
extracellular matrix of osteoblasts was verified by Alizarin Red S
staining (Sigma-Aldrich) and quantified by subsequent dye extrac-
tion as described [13]. To visualize chondrogenic differentiation,
three-dimensional-micromass cultures were immunostained
for Aggrecan (R&D Systems, AF1220) according to standard
procedures (see section Histology and Immunofluorescence
Staining). For quantification of chondrogenesis, cartilage-specific
sulfated proteoglycans and glycosaminoglycans formed in the
micromasses were measured using the Blyscan Glycosaminogly-
can Assay kit (Biocolor, United Kingdom) according to the
manufacturer´s instructions. For assessment of clonogenic
growth, ABCB5+ dermal MSCs and donor-matched ABCB5−
HDFs were seeded at a density of 200 cells per 100 mm cul-
ture dish. After 14 days, colonies were stained with 0.5%
crystal violet (Sigma-Aldrich) and colonies ≥25 cells were
counted on three to five parallel dishes per sample. For clonal
expansion assays, ABCB5+-derived MSCs were seeded at
100 cells per 100 mm culture dish. After 14 days, 12 colonies
separated from neighboring colonies by at least one microscopic field
were picked and expanded. Well-growing clonal cultures were elec-
ted for secondary trilineage differentiation and clonogenic growth
assays.
Human and Mouse Macrophage Cocultures
Mouse bone marrow-derived macrophages were isolated from
femurs and matured for 6 days with macrophage colony-
stimulating factor (M-CSF) containing L929 cell supernatant
supplementation as described [10]. Human macrophages were
matured under presence of 20 ng/ml recombinant human M-CSF
(Miltenyi Biotec, Germany) for 8 days from peripheral blood
mononuclear cell (PBMC)-derived monocytes sorted for CD14
expression by positive magnetic bead selection (Miltenyi Bio-
tec) with purity >95%. Fresh buffy coats for PBMC isolation by
gradient centrifugation were obtained from the German Red
Cross. For coculture experiments, ABCB5+-derived MSCs or
donor-matched ABCB5− HDFs were plated to adhere at 2 × 104
cells per well in 24-well plates in 0.5 ml Dulbecco’s modified
Eagle’s medium with 10% high-quality fetal bovine serum,
100 U/ml penicillin/streptomycin and 2 mM L-glutamine. After
24 hours, macrophages were seeded on top at 1 × 105 cells per
well in 0.5 ml, resulting in a 1:5 cell ratio unless indicated differ-
ently. Cocultures were incubated with 50 U/ml recombinant
mouse or human IFN-γ (R&D Systems) for 24 hours and then
stimulated with 20 ng/ml LPS (Sigma-Aldrich) and 50 U/ml IFN-γ
for another 24 hours period before supernatants were harvested
and analyzed by ELISA (R&D Systems).
Mice and Wound Healing Models
Both female C57BL/6N (Charles River, Germany, strain 027)
and female or male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Jax strain
005557) mice were 10–12 weeks old at the start of experiments
and held under specific pathogen-free conditions in individually
vented cages at the animal facility of the Ulm University. Experi-
ments were performed in compliance with the German law for
welfare of laboratory animals and approved by the Baden-
Württemberg governmental review board.
The C57BL/6 mouse model relevant for chronic venous ulcers
(CVU) physiopathology was performed as described previously
[7]. For cellular treatment with human dermal ABCB5+-derived
MSCs or corresponding ABCB5− HDFs, 1 × 106 cells suspended
in phosphate-buffered saline (PBS) per mouse were injected
into the dermis at three 50 μl injection points around each
wound edge.
For the assessment of wound closure, NSG mice were
humanized with 2 × 107 human PBMC in 200 μl PBS by tail-vein
injection as previously described [14] 8 days before wounding.
At day 1 postwounding, mice were randomly assigned to treat-
ment groups receiving intradermal injection of a six-donor pool
ABCB5+ MSC preparation (Supporting Information Table S1: B01 +
B08 + B09 + B10 + B11 + B12), donor-matched ABCB5− HDFs,
or PBS alone. For the assessment of macrophage phenotype shift,
NSG mice were humanized 1 day before wounding. At day 1
postwounding, random groups were treated with either ABCB5+
MSCs from donor B01 or PBS as described above. At day 5 after
wounding, two independent wound halves of each mouse were
processed for immunofluorescence staining, the others were
pooled for flow cytometry.
www.StemCells.com ©2019 The Authors. STEM CELLS published by
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siRNA-Mediated Knockdown of IL-1RA Expression
in ABCB5+-Derived MSCs
ABCB5+-derived MSCs were transiently transfected with 20 nM of
either a combination of four siRNAs specific for human IL-1RA or
with scrambled control-A siRNA with accompanying transfection
medium at the minimum recommended concentration (all prod-
ucts from Santa Cruz Biotechnologies, Germany) according to
manufacturer’s instructions. Successful knockdown was tested at
the protein level upon in vitro inflammatory stimulation with
IFN-γ/LPS-activated mouse bone marrow-derived macrophages
and culture supernatant medium ELISA for human IL-1RA (R&D
Systems) before use in in vivo experiments and was typically at
80% as shown in Figure 5D.
Histology and Immunofluorescence Staining
Human skin tissue samples were embedded in the O.C.T. com-
pound (TissueTek, Germany), frozen at −80C processed to 5 μm
sections and fixed in acetone. Mouse wounds were fixed over-
night with 4% paraformaldehyde (PFA), cut through the middle,
paraffin embedded, and only the first series of 5 μm sections
were used to avoid the wound edges. Adherent cells were cul-
tured on glass coverslips, fixed with 4% PFA and permeabilized
with 0.5% TritonX-100 in PBS. Sections or slides were incu-
bated with primary antibodies listed in Supporting Information
(Table S3) that were diluted as per manufacturers recommenda-
tions in antibody diluent (DAKO, Germany) at 4C overnight.
Mouse anti-ABCB5 was used at a concentration of 14 μg/ml and
incubation of 40 minutes at 37C for staining of cryosections and
4 μg/ml at 4C overnight for staining of adherent cells. After
washing with PBS, sections or slides were incubated with either
AlexaFluor488- or AlexaFluor555-conjugated corresponding
secondary antibodies (all from Invitrogen, Germany). Nuclei
were counterstained with DAPI before mounting in fluorescent
mounting medium (DAKO). The background staining was con-
trolled by appropriate isotype-matched control antibodies. The
specificity of the anti-ABCB5 staining was assessed by a pep-
tide competition assay, pre-incubating the antibody with a
200-fold molar excess of peptide of the epitope amino acid
sequence [11] (RFGAYLIQAGRMTPEG, GeneCrust) before immu-
nofluorescence staining, showing a loss of the fluorescent
signal.
Masson trichrome (Sigma-Aldrich) and picrosirius red (Poly-
sciences) stainings were performed as per manufacturer’s instruc-
tions on paraffin sections, and picrosirius red stained slides were
analyzed with circularly polarized light. Images were captured
with an AxioImager.M1 microscope, AxioCam MRc camera, and
AxioVision software (Carl Zeiss, Germany).
Human-Specific Beta Actin Sequence-Specific qPCR
Quantification of injected human ABCB5+-derived MSCs and
ABCB5− HDFs within the mouse wound sections was performed
by human-specific beta actin sequence PCR. Briefly, we have
isolated the genomic DNA from PFA-fixed paraffin-embedded
wound sections employing QIAamp DNA FFPE tissue kit (56,404,
Qiagen) followed by PCR with human-specific beta actin primers
(forward primer: CACCACCGCCGAGACCGC and reverse primer:
GCTGGCCGGGCTTACCTG). Then densitometry analysis was
performed to quantify the density of PCR product separated
on the gel images and normalized with mouse-specific beta
actin sequence PCR product. The PCR of mouse beta actin was
performed with mouse-specific beta actin primers (forward primer:
CCTTCCTTCTTGGGTAAGTTGTAGC and reverse primer: CCATACC
TAAGAGAAGAGTGACAGAAATC).
ELISAs and Western Blot
Frozen minced wound tissue samples were dissolved in RIPA
buffer (Sigma) supplemented with protease-inhibitor cocktail
(Roche) and the phosphatase inhibitors Na3VO4 (2 mM) and
NaF (10 mM) in Lysing D columns (MP Biomedicals, Germany)
subjected to three rounds of 20 seconds cooled vibrational
force. Protein yield was measured by Bradford assay and spec-
trophotometric analysis against a bovine serum albumin
(BSA)-standard dilution. All ELISA assays were performed with
DuoSet kits (R&D Systems) following manufacturer’s instruc-
tions. Western blot analysis for IL-1RA was performed as ear-
lier published [15]. A rabbit anti-IL-1RA IgG1 antibody (Abcam,
Germany #ab124962) which detects human and murine IL-
1RA at a dilution of 1:1000 and a secondary HRP-coupled anti-
rabbit IgG (H + L) antibody (Dianova, Germany) at a dilution of
1:10,000 were used. Equal loading was verified by actin. Chemilu-
minescence was detected after addition of LumiGLO chemilumi-
nescent substrate (Cell Signaling, Germany) with a Vilber Fusion
Fx7 (Vilber Lourmat, Germany).
Flow Cytometry
Flow cytometry for ABCB5 was performed using anti-ABCB5
mouse IgG1 (clone 3C2-1D12; [11]) and secondary AlexaFluor647-
conjugated donkey anti-Mouse IgG (H + L) (Fisher Scientific,
Germany). Multicolor labeling of cells for the MSC-marker
panel CD90, CD73, and CD105 as well as for CD34, CD14, CD20,
and CD45 was performed with the human MSC phenotyping kit
(Miltenyi Biotec) following the manufacturer´s instructions. Anti-
human SSEA-4-PE, CD271-FITC, CD133, CD318, and Melan-A anti-
bodies (Supporting Information Table S3) were incubated with
the cells for 45 minutes at 4C at concentrations recommended
by the manufacturer. For the detection of CD133, CD318, and
Melan-A, cells washed with fluorescence-activated cell sorting
(FACS)-buffer (1% BSA in PBS) were subsequently incubated with
fluorochrome-conjugated secondary antibodies for 45 minutes at
4C. Dead cells were excluded by costaining with SYTOX Blue
(Invitrogen). Isotype-matched control antibodies were used for
setting of gates.
For wound macrophage isolation, mouse wounds were
digested as previously described [16, 17]. Briefly, minced tissues
were incubated with 1.5 mg/ml collagenase I and 1.5 mg/ml
hyaluronidase I (Sigma-Aldrich) in HEPES-buffered saline for
1 hour at 37C. Single cell preparations were filtered and incu-
bated for 15 minutes with FcR blocking (MACS) before staining
with antibodies listed in Supporting Information Table S3. Addi-
tional intracellular stainings were performed after fixation and
permeabilization using a commercial kit (BD, Germany) according
to the manufacturer’s protocol. Blank and single-stained samples
were used for photomultiplier (PMT) and compensation settings.
For wound macrophages, singlet F4/80+ mouse macrophages in
C57BL/6N samples and singlet CD68+ human macrophages in
humanized NSG mouse samples were gated (Supporting Informa-
tion Fig. S11) for subsequent M1 and M2 marker expression anal-
ysis based on relative fluorescence units (= geomean fluorescence
intensity relative to isotype control sample) or % positive events
within the macrophage population. Hereto, positivity thresholds
were set against the relevant fluorescence-conjugated isotype
©2019 The Authors. STEM CELLS published by
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controls and macrophage gating marker stained control sam-
ples. Flow cytometry was performed on FACSCanto II, FACSAria
Fusion, or Accuri flow cytometers (BD Biosciences, Germany),
and the data thereafter analyzed using FlowJo analysis software
(TreeStar Inc., USA).
Comprehensive Transcriptome Profiling and
Quantitative PCR
To prepare the total RNASeq library, 500 ng of total RNA was
used as input. First, 500 ng of total RNA was used to deplete the
rRNA using a commercially available kit (Low Input Ribominus
Eukaryotic System v2, Thermo, Germany) as described in the
manual with slight modifications. In brief, after the rRNA was
depleted using RiboMinus Eukaryote Probe Mix, the supernatant
containing rRNA-depleted RNA was collected and incubated with
3x Agencourt RNAClean XP beads for 20 minutes on ice, followed
by removal of supernatant and washing of RNAClean XP beads
2 times with 80% ethanol, and finally the rRNA depleted RNA
was eluted from the beads in 10 μl of nuclease-free water. This
rRNA depleted RNA was used to prepare RNASeq library for
Illumina platform using NEBNext Ultra II Directional RNA library
prep kit (NEB, Germany) with some modifications. The quality
control of the RNASeq libraries was performed by Agilent Bio-
analyzer, and concentration of the libraries were measured in
qubit using dsDNA HS assay kit (Thermo). The libraries were
sequenced in Illumina NextSeq 500 system for 75 cycles (1 × 75
single end reads) of sequencing and two index reads of eight
cycles each using NextSeq 500/550 v2 Kits (Microsynth AG,
Switzerland). The demultiplex raw reads (fastq) were used for
gene expression analyses as described earlier [18]. In brief, the
fastq files were used to align to human genome reference
(GRCh38) using Hisat2, followed by transcripts assembly, and
abundances estimation and differential expression were per-
formed by cufflinks and cuffdiff, respectively. The visualization of
RNASeq data analyses was performed by R packages, cummeR-
bund, gplots, and ggplot2 using customized scripts.
Statistical Analysis
Statistical analysis of in vitro and in vivo differences in inde-
pendent quantitative measures between every two treatment
groups was performed using two-sided unpaired Student’s
t tests with Welch correction to protect against heteroscedastic
data sets. in vitro comparisons for ABCB5+ and donor-matched
ABCB5− cell fractions were analyzed by a paired t test. On rare
occasions, outliers detected by visual inspection of the data were
excluded from the analysis after post hoc verification by the
Grubbs’ test at α = 5%. Statistical data analysis was done using
GraphPad Prism 6 software (Software for Science). Graphs show
mean, and error bars represent the standard deviation unless
indicated otherwise and stars represent significance levels:
ns = not significant; *, p < .05; **, p < .01; ***, p < .001.
RESULTS
Human and Murine Dermis Harbor ABCB5+ Stromal
Cells in the Perivascular and Interfollicular Niche
Using immunostaining of healthy human skin sections, we
demonstrate that ABCB5+ cells costain for the carbohydrate
stage-specific embryonic antigen-4 (SSEA-4) (Fig. 1, 1B), an
embryonic germ and stem cell marker [19] earlier reported to
be expressed on MSCs in different adult tissues, including the
dermis [20–22].
Interestingly, ABCB5+ cells either were confined to a peri-
vascular endogenous niche, in close association with CD31+
endothelial cells, or were dispersed within the interfollicular
dermis independent of hair follicles (Fig. 1C). ABCB5+ cells con-
stituted 2.45%  0.61% of all dermal cells in the skin of 10 dif-
ferent donors and of the ABCB5+ cells and 55.3%  23.9%
were localized perivascularly, which was defined as a maximum
of one additional cell in between the CD31+ endothelial cell
and the ABCB5+ cell (Fig. 1D). Perivascular ABCB5+ cells were
distinct from neural/glial antigen 2 (NG2) positive pericytes [23],
as there was almost no colocalization of NG2 with ABCB5
in double immunostained human skin sections (Fig. 1E, 1F).
A similar distribution of ABCB5+ cells in their endogenous niche
was found in murine skin (Supporting Information Fig. S1).
Moreover, RNA sequence analysis from ABCB5+-enriched
MSCs—even when expanded in culture to high passage numbers—
revealed expression of distinct stemness as well as mesenchymal
marker genes (Supporting Information Fig. S2A, S2B). Further-
more, we confirmed the expression of selected stemness markers
such as SSEA-4, DPP4 (CD26), PRDM1 (BLIMP1), and POU5F1
(OCT-4) in ABCB5+ cells in human skin at protein level by immu-
nostaining (Supporting Information Fig. S2C–S2F), although the
expression of lower fibroblast lineage marker α-smooth muscle
actin (α-SMA) was absent in ABCB5+ cells of human skin
(Supporting Information Fig. S2G). Together these results sup-
port stemness properties of ABCB5+ cells that are at least in part
maintained in vitro and can be exploited therapeutically for the
treatment of nonhealing wounds.
Human Dermal ABCB5 Cells Reveal MSC Properties
To assess whether selection for ABCB5 results in a cell fraction
with MSC properties, dermal single cell suspensions derived
from enzymatically digested skin were separated by multiple
rounds of ABCB5 magnetic bead sorting. This resulted in two
different cell fractions, a double ABCB5-enriched fraction con-
taining on average 98.33%  1.12% ABCB5+ cells and a three-
fold ABCB5-depleted fraction which only contained a very low
percentage of ABCB5+ cells as illustrated with flow cytometry
dot plots for cells from donor B01 (Fig. 2A; Supporting Infor-
mation Table S1A, S1B). Both ABCB5+ and ABCB5− fractions
displayed a fibroblastoid, spindle-like cell morphology (Fig. 2B)
and expressed the characteristic minimal set of mesenchymal
lineage markers CD90, CD105, and CD73, whereas no expres-
sion of hematopoietic stem cell and lineage markers CD34,
CD14, CD20, and CD45 [24] was detected by flow cytometry
(Fig. 2C). A consistent and significantly increased potential for
adipogenic, osteogenic, and chondrogenic lineage differentiation
was observed for ABCB5+ cells as compared with donor-matched
ABCB5-depleted cells (Fig. 2D–2F), thereby delineating the
ABCB5+ fractions as multipotent adult MSCs from ABCB5−
HDFs. This was further confirmed by the finding that ABCB5+
sorted cells gave rise to single-cell-derived colonies, whereas
the ABCB5-depleted fractions did not (Fig. 2G). To assess the
in vitro self-renewal capacity of dermal ABCB5+-derived MSCs,
subclonogenic growth and trilineage differentiation potential of
54 clonal cultures of ABCB5+-sorted MSCs from six different
donors were determined (Fig. 2H). Interestingly, 75.61% 
16.86% of clonal colonies again displayed clonogenic growth
and 62.40%  7.54% of all studied clones, generated from a
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single cell, maintained their potential to differentiate into all
three mesenchymal cell lineages (Fig. 2H). An additional
29.84%  11.57% of these clones were bipotent and
7.77%  10.02% were unipotent for osteogenic differentia-
tion (Fig. 2H). None of the clones from six donors were nega-
tive for all three lineages. When compared with the gold-
Figure 1. In situ characterization of ABCB5+ cells in their endogenous niche in healthy human skin. (A, B): A microphotographic overview of
healthy human skin subjected to immunostaining for ABCB5 (green) and the adult stem cell marker SSEA4 (red) revealed a distinct subpopula-
tion of dermal cells positive for both markers (yellow overlay). Quantification of ABCB5 positive and SSEA-4 positive proved that 94.39% of der-
mal cells expressing ABCB5 were copositive for SSEA-4. (C): Microphotographs of human skin subjected to immunostaining for ABCB5 (green)
and the endothelial marker CD31 (red) revealed both a perivascular (left) and a dispersed interfollicular dermal localization (right) of ABCB5+
cells (white arrows), whereas no colocalization of ABCB5 and CD31 was observed. (D): ABCB5+ cells occurred at an average percentage of
2.45  0.61 of all dermal cells as determined in 8–10 microscopic fields of skin sections from 10 different donors. ABCB5+ cells were more abun-
dant in a perivascular localization compared with a nonperivascular localization. (E): Double immunofluorescence staining for ABCB5 (green)
and the pericyte marker NG2 (red) shows that perivascular ABCB5+ cells (white arrows) are distinct from NG2+ pericytes. (F): Quantification of
ABCB5 positive and NG2 positive depict that only 0.32% of total dermal cells coexpressed ABCB5 and NG2 as determined in more than 20 micro-
scopic fields of skin sections from five different donors. (A, B, D): Nuclei of all studied skin sections were counterstained with DAPI (blue). Scale
bars = 50 μm; e = epidermis; d = dermis. Dashed white lines delineate epidermal from dermal layers. Abbreviations: ABCB5, ATP-binding cas-
sette subfamily B member 5; DAPI, 40,6-diamidino-2-phenylindole; NG2, neural/glial antigen 2; SSEA-4, stage-specific embryonic antigen-4.
©2019 The Authors. STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press 2019
STEM CELLS
1062 Dermal ABCB5+ MSCs Promote Chronic Wound Healing
Figure 2. In vitro characterization of ABCB5+ dermal cells. (A): Flow cytometry reproducibly confirmed high purity of ABCB5+ and ABCB5−
dermal cell fractions. (B): Differential interference contrast micrographs depict a fibroblast-like phenotype for both ABCB5+ and ABCB5− frac-
tions. (C): Flow cytometry results show that both fractions expressed CD90, CD73, and CD105 and lacked CD14, CD20, CD34, and CD45
expression (black). Gray histograms represent isotope controls. (D–F): in vitro trilineage differentiation was more prominent for ABCB5+ than
for ABCB5-depleted dermal cells. Adipogenic and osteogenic differentiation was quantified by extraction of respective ORO (D) and ARS (E)
indicator dyes. Chondrogenic differentiation (F) was visualized by aggrecan immunostaining (red) and quantitatively assessed by extraction
of sGAG. (G): Following low-density seeding, only cells from ABCB5+-sorted fractions formed crystal violet-visualized colonies. (H): ABCB5+-
sorted cell clonal cultures were subjected to a second CFU assay and tri-lineage (O = osteogenic; A = adipogenic; C = chondrogenic) differen-
tiation. Threshold for clonogenic growth (five colonies) and positive differentiation was set 3 SD above the average from ABCB5− samples or
unstimulated controls, respectively. (I): SSEA-4+ cells by flow cytometry and SOX2+ nuclei (red) by immunofluorescence staining were found
exclusively within ABCB5+ fractions. Nuclei are counterstained with DAPI (blue). Scale bars = 50 μm. **, p < .01; ***, p < .001, t test. Abbrevi-
ations: ABCB5, ATP-binding cassette subfamily B member 5; CFU, colony-forming unit; DAPI, 40,6-diamidino-2-phenylindole; sGAG, sulfated
glycosaminoglycans; SSEA-4, stage-specific embryonic antigen-4; ORO, Oil Red O; ARS, Alizarin Red S; SSC, Side scatter.
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Figure 3. Human ABCB5+-derived MSCs accelerate impaired wound healing by inducing a switch from classically activated M1 to regenera-
tive M2 macrophages. (A): Coculture of human dermal ABCB5+-derived MSC with human macrophages matured from peripheral blood
monocytes at a ratio of 1:5 significantly downregulates the secretion of the proinflammatory M1 cytokines TNFα (left) and IL-12/IL-23p40
(middle) upon classical IFN-γ/LPS activation as measured by enzyme-linked immunosorbent assay. The anti-inflammatory M2 cytokine IL-10
(right) was upregulated upon ABCB5+-derived MSC macrophage coculture. By contrast, donor-matched ABCB5− HDFs did not show any
change in cytokine release when cocultured with activated macrophages. (B): In a cross-species, 1:5 coculture setting of human dermal
ABCB5+-derived MSCs or donor-matched ABCB5− HDFs, respectively, with mouse macrophages revealed similar results as in (A). (C): Scheme
depicting the timeline for the iron-overload mouse model used. Intraperitoneal iron-dextran injections and intradermal injections into
wound edges were performed as illustrated. (D): Persistence and localization of ABCB5− cells and ABCB5+-derived MSCs within the wound
bed at day 3 was visualized by immunostaining for human β2M (red). The negative control showing immunostaining of a section of a mouse
wound in the absence of any human-derived MSCs injections. Scale bars = 100 μm; e = epidermis; d = dermis. Dashed white lines delineate
epidermal from dermal layers. Nuclei were DAPI counterstained (blue). (E): ABCB5+ MSCs and ABCB5− MSCs were detected and quantified
in wounds at indicated time points postwounding by human beta actin sequence polymerase chain reaction; ns, nonsignificant. (F): Ruler-
assisted size-equalized wound pictures representative for defined interventions at the indicated time points after wounding. (G): Quantification
(Figure legend continues on next page.)
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standard of bone marrow-derived MSCs with a trilineage differ-
entiation capacity of 34% in more than 200 studied single-cell
clones [25], the trilineage differentiation capacity >70% was
apparently better in ABCB5+ skin-derived MSCs.
In contrast to triple ABCB5-depleted cells, the ABCB5+-sorted
cell fractions revealed distinct stem-cell-associated SSEA-4 [26]
expression (Fig. 2I). This matches with the observed coexpression
of ABCB5+ cells with SSEA-4 in human skin (Fig. 1A). Nuclei of
ABCB5+ cells grown on slides stained positive for SOX2, the stem-
cell-associated transcription factor sex determining region Y-box
2, whereas ABCB5− cells did not (Fig. 2I). Neither ABCB5+ nor
ABCB5− dermal plastic-adherent cell fractions expressed the
additionally tested cell surface markers Melan-A (melanocytic
cells), CD133 (cancer stem cells), CD318 (epithelial cells). and
CD271 (a neurotrophic factor found on other MSC populations;
Supporting Information Fig. S3).
Human ABCB5+-Derived MSCs Accelerate Wound
Healing in Iron-Overload Mice Through Triggering a
Switch from M1 to M2 Macrophages
In order to address whether the here characterized dermal
ABCB5+-derived MSCs exert anti-inflammatory effects on clas-
sically activated M1 macrophages, ABCB5+-derived MSCs were
cocultured with allogeneic PBMC CD14+ monocyte-derived
macrophages that had been activated with recombinant human
IFN-γ and LPS (Fig. 3A). Of note, significantly less M1 macrophage-
derived proinflammatory cytokines TNFα and IL-12/IL-23p40 were
detected in supernatants when activated macrophages were
cocultured with ABCB5+-derived MSCs, as opposed to cocultures
with donor-matched ABCB5− HDFs or macrophages cultured
alone. Conversely, increased amounts of IL-10, a M2 macrophage-
derived anti-inflammatory cytokine, were found in superna-
tants of macrophages cocultured with ABCB5+-derived MSCs
as opposed to donor-matched ABCB5− HDFs or macrophages
cultured alone (Fig. 3A). Of note, pooled ABCB5+-derived MSCs
from six different donors revealed a similar suppressive action
on M1 macrophage cytokines with a concomitant upregulation
of the M2 macrophage cytokine IL-10 when compared with
the single ABCB5+-derived MSCs (Supporting Information Fig. S4).
These data imply that pooled preparations of ABCB5+-derived
MSCs would be a practically relevant option for the treatment
of nonhealing wounds in clinical routine.
Similar to cocultures of human ABCB5+-derived MSCs with
human macrophages, human ABCB5+-derived MSCs exert iden-
tical effects on murine macrophages in a cross-species setting
(Fig. 3B; Supporting Information Fig. S4), thereby confirming
functional relevance for subsequent wound healing studies in
a murine xenograft model.
Next, in order to specifically investigate the paracrine effects
of ABCB5+-derived MSCs on suppression of M1 macrophages,
which—due to their unrestrained activation—are responsible
for the nonhealing state of chronic human wounds, we used
the iron-overload mouse model [7] with full-thickness exci-
sional wounds in a xenograft setting. The iron-overload wound
model faithfully recapitulates major pathogenic aspects of
chronic venous leg ulcers [7]. ABCB5+-derived and ABCB5-depleted
dermal human cells were injected into the dermis around the
wound edges at day 1 after wounding as graphically depicted
(Fig. 3C). The persistence of injected human cells at day 3 after
wounding was confirmed by immunostaining for the human major
histocompatibility complex I constant subunit β2-microglobulin
(β2M) (Fig. 3D). By means of human-specific beta actin sequence
PCR on genomic DNA isolated from wound sections, we con-
firmed persistence of human-specific beta actin-signals to a sim-
ilar extent in the wounds injected with either ABCB5+-derived
MSCs or ABCB5− cells at indicated time points (Fig. 3E). Therefore,
differences in the persistence between ABCB5+ and ABCB5−
cells did not confound our results.
We next addressed the question whether injection of
ABCB5+-derived MSCs accelerate wound closure in the iron-
overload model. As expected, we observed delayed wound
closure in iron-treated/PBS-injected mice as compared with
dextran-treated/PBS-injected control mice (Fig. 3F, 3G). Of
note, a significantly accelerated wound closure was observed
after intradermal injection of 106 ABCB5+-derived MSCs around
four wounds (per mouse) compared with injection of donor-
matched ABCB5− HDFs or PBS alone (Fig. 3F, 3G). Treatment
with ABCB5+-derived MSCs fully restored the wound closure rate
to that of dextran-treated/PBS-injected control mice (Fig. 3F, 3G).
Together these findings suggest beneficial effects of ABCB5+-
derived MSCs for the cure of nonhealing chronic wounds.
Human ABCB5+-Derived MSCs Suppress Inflammation
and Improve all Subsequent Wound Phases in Iron-
Overload Mice
Chronic wounds persist in the inflammatory wound phase with
unrestrained M1 macrophage activation and fail to progress
through the normal phases of wound healing. We here studied
whether injection of ABCB5+-derived MSCs may suppress the
unrestrained M1 macrophage-dependent inflammation and allow
the wounds to follow the normal sequence of different wound
phases. Employing double immunostaining, we found ABCB5+-
derived MSCs in close association to endogenous murine macro-
phages when injected in iron-overload wounds (Supporting
Information Fig. S5), implying that a paracrine effect of ABCB5+-
derived MSCs on macrophages is possible in wound tissue. In a
first attempt to explore a paracrine impact of ABCB5+-derived
MSCs on macrophage-dominated inflammation in iron-overload
wounds, whole wound cytokine profiles were studied by ELISA
on protein lysates (Fig. 4A). Notably, at day 5 after wounding,
wound tissue protein levels of the inflammatory cytokine TNFα
were dampened (Fig. 4A), whereas anti-inflammatory IL-10 was
increased in iron-overload wounds injected with ABCB5+-derived
MSCs but not with ABCB5− HDF controls (Fig. 4A). Furthermore,
the inflammatory cytokine IL-1β, that is typically upregulated in
human CVU (Supporting Information Fig. S6A, S6C) and in iron-
overload murine model (Supporting Information Fig. S6B, S6D),
(Figure legend continued from previous page.)
of wound areas depicted in (F) relative to day 0 confirmed delayed wound closure in the iron-model (open squares) compared with
dextran-injected control wounds (open circles). Wound healing delay in the iron-model was rescued by ABCB5+-derived MSCs (blue
squares) but not by ABCB5− HDFs (black squares). ns = not significant; *, p < .05; **, p < .01; ***, p < .001, t test. Abbreviations: ABCB5,
ATP-binding cassette subfamily B member 5; DAPI, 40,6-diamidino-2-phenylindole; HDF, human dermal fibroblasts; IL, interleukin; MSC,
mesenchymal stem cells; PBS, phosphate-buffered saline; TNFα, tumor necrosis factor alpha.
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Figure 4. ABCB5+ MSCs rescue imbalanced wound healing in iron-overload mice. (A): Opposed to ABCB5−-derived HDFs, ABCB5+-derived
MSC suppressed M1 cytokines (TNFα, IL-1β), whereas increased M2-associated IL-10 (assessed by ELISAs) (n = 4). (B): Keratin14 immunostaining
(green) illustrates incomplete (left) and complete (middle) re-epithelialization. Percentages of re-epithelialized wounds over treatment groups
(right) indicate faster epithelial closure upon ABCB5+-derived MSC treatment (blue) as compared with PBS (dashed red) or ABCB5− HDFs con-
trols (black). (C): Impaired neoangiogenesis in the iron-overload wound model, assessed by CD31 immunostaining (red), was fully rescued with
ABCB5+-derived MSC supplementation. (D): Number and size of CD31+ vessel sprouts confirmed this (n = 6). (E): Picrosirius red histology indi-
cated advanced matrix constitution of the outlined granulation tissue (gt) with more collagen fibers (yellow-red bifringence) following ABCB5+-
derived MSC treatment. (F): Reduced gt thickness (white arrows in E) was found for ABCB5+-derived MSC-injected wounds when compared
with iron-model controls. (G): Masson trichrome illustrates densely woven collagen matrix proteins (blue) following ABCB5+-derived MSC injec-
tion, comparable to acute wounds. Scale bars = 100 μm. (H): Scar tensile strength was significantly improved in ABCB5+-derived MSC-injected
iron-overload wounds. (B, C, E): Scale bars = 200 μm; e = epidermis; d = dermis. Dashed lines delineate epidermis from dermis. Nuclei were
DAPI-counterstained (blue) (B, C). *, p < .05; **, p < .01; ***, p < .001, t test. Abbreviations: ABCB5, ATP-binding cassette subfamily B member 5;
DAPI, 40,6-diamidino-2-phenylindole; HDF, human dermal fibroblasts; IL, interleukin; MSC, mesenchymal stem cells; PBS, phosphate-buffered
saline; TNFα, tumor necrosis factor alpha.
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was significantly suppressed upon treatment with ABCB5+-derived
MSCs (Fig. 4A, right panel).
We also observed faster re-epithelialization with a fully restored
K14+ epithelial cell layer covering the entire wound bed, a key
feature of successful skin repair, in day 7 iron-overload wounds
when injected with ABCB5+-derived MSCs as opposed to ABCB5−
HDF-injected wounds (Fig. 4B). We observed a significant improve-
ment of neovascularization (Fig. 4C) as confirmed by increased
Figure 5. ABCB5+-derived MSCs rescue delayed wound healing via IL-1RA secretion. (A): ABCB5+-MSCs cultured alone (black bars) or with murine
macrophages, secreted IL-1RA following IFN-γ/LPS stimulation, whereas ABCB5− HDFs did not. (B): Production of human IL-1RA+ (green) by β2M+
(red) human ABCB5+-derived MSCs was observed 6 hours after ABCB5+ MSCs injection around iron-overload wounds. Scale bars = 50 μm.
(C): A 22 kDa band for lysates of three pooled ABCB5+-derived MSCs-injected day 3 wounds, but not in ABCB5− HDF-injected wounds, was
detected by human IL-1RA-specific immunoblotting. (D): IL-1RA silencing in ABCB5+-derived MSCs abrogated adaptive upregulation of IL-1RA
(hatched bars) and significantly diminished TNFα suppression in activated murine (black bars) and human (white bars) macrophages in
corresponding cocultures. (E): Rescued wound healing and decreased wound areas following ABCB5+-derived MSC injection (blue squares) in iron-
overload mice was almost completely abrogated in IL-1RA siRNA (red diamonds) but not control siRNA transfected ABCB5+-derived MSCs (blue dia-
monds) from day 5 wounds onward. (F): Day 5 proinflammatory cytokine profiles of iron-overload wounds remained unaltered when IL-1RA
silenced ABCB5+-derived MSCs had been injected. (A, D, F): Bar graphs represent ELISA results. Significance level indications relate to control acti-
vated macrophages alone (A), respective siRNA-transfected groups (D) and PBS-treated group (F). *, p < .05; **, p < .01; ***, p < .001, t test. Abbre-
viations: ABCB5, ATP-binding cassette subfamily B member 5; DAPI, 40,6-diamidino-2-phenylindole; HDF, human dermal fibroblasts; IL, interleukin;
IL-1RA, interleukin-1 receptor antagonist; MSC, mesenchymal stem cells; PBS, phosphate-buffered saline; TNFα, tumor necrosis factor alpha.
www.StemCells.com ©2019 The Authors. STEM CELLS published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press 2019
Vander Beken, de Vries, Meier-Schiesser et al. 1067
Figure 6. ABCB5+-derived MSCs mediate a shift from M1 to anti-inflammatory M2 wound macrophages via IL-1RA. (A): Representative
microphotographs of double immunostaining for macrophage F4/80 (green) and murine TNFα (red) in skin sections of day 5 wounds illus-
trate reduction of M1 macrophages following injection with ABCB5+-derived MSCs but not ABCB5− HDFs at the wound margins. This M1
macrophage suppressive effect was abrogated when IL-1RA silenced ABCB5+ MSCs were injected. (B): Double immunostaining for F4/80
(green) and the M2 marker CD206 (red) displayed an IL-1RA-dependent increase in M2 macrophages in iron-overload wounds, compara-
ble to M2 macrophage numbers in physiological wound healing controls (Dextran/PBS) at day 5 postwounding. (A, B): Scale bars = 50 μm;
inserts are three-fold enlarged. Nuclei are stained with DAPI (blue). (C): Multi-color flow cytometry on singlet F4/80+ wound single cell
preparations at day 5 postwounding confirm a wound macrophage immune-phenotype shift with downregulation of M1 markers like
TNFα, IL-12/IL-23p40, and NOS2 and upregulation of the M2 markers CD206, Dectin-1, and ARG1 IL-1RA-dependently mediated by ABCB5+
MSCs but not by donor-matched ABCB5− HDFs. ns = not significant; *, p < .05; **, p < .01; ***, p < .001, t test. Abbreviations: ABCB5, ATP-binding
cassette subfamily B member 5; DAPI, 40,6-diamidino-2-phenylindole; HDF, human dermal fibroblasts; IL, interleukin; IL-1RA, interleukin-1 receptor
antagonist; MSC, mesenchymal stem cells; PBS, phosphate-buffered saline; TNFα, tumor necrosis factor alpha.
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number and area of CD31+ vessel sprouts within the wound bed
at day 7 (Fig. 4D). In addition, injection of ABCB5+-derived MSCs
in wound edges of iron-overload mice markedly improved the
tissue remodeling with increased maturation of collagen fibers
(Fig. 4E), reduced granulation tissue depth (Fig. 4F), and improved
organization of collagen fibers in more densely basket-woven
fibrillary structure (Fig. 4G). Of note, iron-overload wounds injected
with ABCB5+-derived MSCs depicted a significantly higher tensile
strength of the scar tissue, a strong indication for improved quality
of the restoration tissue, as compared with less tensile strength in
scar tissue of ABCB5− HDF or PBS-treated iron-overload wounds
(Fig. 4H). These data show that ABCB5+-derived MSCs positively
impact on several wound healing phases and not only accelerate
tissue repair but importantly lead to a scar-reduced, quality-
improved restoration tissue.
ABCB5+-Derived MSCs Suppress
Macrophage-Dominated Inflammation via Adaptive
Secretion of IL-1RA
Given the abundance of IL-1β and its inflammation amplifying
effector TNFα [7] in chronic wounds as opposed to transiently
induced low IL-1β concentrations in acute wounds, we addressed
the question as to whether human dermal ABCB5+-derived MSCs
are able to produce the natural antagonist of IL-1 signaling,
IL-1RA. We found that unstimulated ABCB5+-derived MSCs in cul-
ture did not readily produce IL-1RA as assessed by a specific ELISA
(Fig. 5A). However, in contrast to donor-matched ABCB5− HDFs,
ABCB5+-derived MSCs released high IL-1RA levels when stimulated
with IFN-γ /LPS (Fig. 5A). Of note, the IL-1RA concentration was
even higher in cocultures of ABCB5+-derived MSCs with IFN-γ/LPS-
activated M1 macrophages (Fig. 5A). Six hours after injection, spe-
cific IL-1RA expression was observed in ABCB5+-derived MSCs at
the wound site of iron-overload mice as shown by double immu-
nostaining with distinctly colocalized human-specific β2M and
IL-1RA (Fig. 5B). Employing Western blot analysis, we confirmed
high IL-1RA expression in pooled day 3 wound lysates prepared
from iron-overload ABCB5+-derived MSCs-injected wounds as com-
pared with no IL-1RA expression in ABCB5− HDFs or in PBS-injected
control wound lysates (Fig. 5C). Of note, and previously unreported,
we also observed IL-1RA expression in endogenous murine
ABCB5+ MSCs in iron-overload model wound healing, whereas in
healthy skin, neither murine nor human endogenous ABCB5+-
derived MSCs were found to express IL-1RA (Supporting Informa-
tion Fig. S7). These data imply an adaptive production of IL-1RA by
dermal ABCB5+ MSCs in response to the inflammatory environ-
ment of iron-overload wounds. A small fraction of murine macro-
phages, but not neutrophils, release IL-1RA in iron-overload
chronic wounds (Supporting Information Fig. S8). The therapeutic
impact of IL-1RA released from ABCB5+-derived MSCs on accelera-
tion of healing of iron-overload wounds is, however, significantly
more important, as IL-1RA-silenced MSCs, when injected into iron-
overload wounds, cannot restore delayed wound healing. We next
explored whether IL-1RA released by ABCB5+-derived MSCs are
responsible for the suppression of M1 macrophage-derived TNFα
in vitro and in vivo. ABCB5+-derived MSCs were assessed for TNFα
release in wounds supernatants of iron-overload mice injected
with either IL-1RA silenced or competent ABCB5+-derived MSCs.
Notably, silencing of IL-1RA in ABCB5+-derived MSCs at least par-
tially abrogated TNFα suppression in cocultures with either human
or murine macrophages (Fig. 5D). As expected, scrambled control
siRNA transfected IL-1RA competent control ABCB5+-derived MSCs
revealed their full suppressive effect on TNFα release from acti-
vated macrophages in vitro (Fig. 5D). Strikingly, intradermal injec-
tion of IL-1RA silenced ABCB5+-derived MSCs into wound edges of
iron-overload mice resulted in a complete loss of accelerated
wound closure (Fig. 5E). By contrast, scrambled siRNA transfected
IL-1RA competent ABCB5+ MSCs maintained their capacity to
accelerate wound healing at the indicated time points in vivo
(Fig. 5E). The loss of the capacity of IL-1RA silenced ABCB5+ MSCs
to accelerate healing in iron-overload wounds was associated with
a reversal of TNFα and IL-1β suppression and IL-10 upregulation
(Fig. 5F). These data indicate that IL-1RA adaptively released from
ABCB5+ MSCs upon stimulation at the wound site not only sup-
presses IL-1 signaling but also the downstream effector TNFα and,
importantly, even induces anti-inflammatory IL-10. The notion that
IL-1RA released from ABCB5+-derived MSCs at the wound site
suppressed unrestrained M1 activation with improved wound
healing is further supported by our finding that intradermal injec-
tion of recombinant human IL-1RA around iron-overload wounds
also accelerated wound closure (Supporting Information Fig. S9A).
By contrast, injection of recombinant IL-1RA into acute wounds
did not accelerate healing (Supporting Information Fig. S9B). We
also found tumor necrosis factor-inducible gene 6 (TSG-6) to be
expressed in ABCB5 human MSCs in iron-overload wounds
(Supporting Information Fig. S10A, S10B). However, when injecting
recombinant TSG-6 into iron-overload wounds, no improvement
of wound closure occurred (Supporting Information Fig. S10C).
Our results imply that IL-1RA, indeed, plays a central role in iron-
overload wounds, whereas recombinant human TSG-6 alone is
not sufficient to accelerate healing in the iron-overload situation.
This implies that different wound types reveal distinct require-
ments for therapeutic acceleration of their healing.
ABCB5+-Derived MSCs Break M1 Macrophage
Persistence in Wounds of Iron-Overload Mice
To further sustain the hypothesis that wound treatment with
ABCB5+-derived MSC would IL-1RA-dependently break the pro-
longed persistence of M1 macrophages in wounds of the iron-
overload mice, a series of double immunostainings of day
5 wound sections were performed. In fact, TNFα expressing
F4/80+ macrophages were virtually absent in iron-overload
wounds injected with ABCB5+-derived MSCs (Fig. 6A). In stark
contrast, many TNFα+ F4/80+ double positive macrophages
persisted in wound margins upon injection of IL-1RA silenced
ABCB5+-derived MSCs similar to dextran pretreated acute
healing control mice (Fig. 6A). These data indicate that ABCB5+-
derived MSCs IL-1RA-dependently suppress wound macrophage
released TNFα production in vivo. Interestingly, CD206+ F4/80+
wound healing-promoting M2 macrophages appeared to be
IL-1RA-dependently enriched in ABCB5+-derived MSCs-injected
wounds at day 5 postwounding (Fig. 6B). In fact, immune
phenotyping of single cell preparations of day 5 wounds injected
with ABCB5+-derived MSCs (Supporting Information Fig. S11A)
quantitatively confirmed an IL-1RA-dependent switch of inflam-
matory M1 toward wound healing-promoting M2 macrophages
as defined by distinct sets of surface markers (Fig. 6C). Thus,
M1 activation markers, including cytokines (TNFα and IL-12/
IL-23p40) and the inducible nitric oxide synthase (NOS2) were
downregulated and M2 activation markers like the mannose
receptor CD206, the β-glycan Dectin-1, and arginase-1 (ARG1)
were upregulated in F4/80+ wound macrophages after ABCB5+-
derived MSCs injection (Fig. 6C). This M1 to M2 shift was
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maintained in scrambled siRNA transfected ABCB5+-derived MSCs,
whereas it was almost completely abrogated following injection
with IL-1RA siRNA transfected ABCB5+-derived MSCs (Fig. 6C,
outer right lower panel). In aggregate, these results uncover a
causal role for IL-1RA to abrogate persistence of M1 macrophage
in chronic wounds secreted by ABCB5+-derived MSCs.
The ABCB5+-Derived MSCs-Dependent M1 to M2
Macrophage Shift Is Conserved in Humanized
NSG Mice
NSG mice, humanized with PBMC, represent a highly suitable
preclinical model to investigate effects of therapeutic interven-
tions on human hematopoietic lineage-derived cells in vivo [14].
This model was used here to validate the effect of ABCB5+-
derived MSC injection on the M1/M2 wound macrophage
phenotype of human origin in NSG iron-overload mice. For this
purpose, full-thickness wounds were inflicted on PBMCs human-
ized NSG mice with subsequent intradermal injection of human
allogeneic ABCB5+-derived MSCs, donor-matched ABCB5− HDFs, or
PBS alone into the wound edges. In line with our above findings,
accelerated closure of full-thickness wounds upon injection with
ABCB5+-derived MSCs was observed compared with PBS and
ABCB5− HDF injection of wounds in PBMC-humanized NSG mice
(Fig. 7A). Coimmunostaining of day 5 wounds with human-
specific anti-CD68 and either anti-CD206 or anti-TNFα showed a
higher number of CD68+ CD206+ human M2 macrophages in the
wound beds of ABCB5+-derived MSC-injected compared with
PBS-injected wounds (Fig. 7B). Of note, the number of CD68+
TNFα+ proinflammatory macrophages was decreased in ABCB5+-
derived MSCs compared with PBS-injected wounds (Fig. 7B).
Single-cell suspensions derived from day 5 wound tissue were
analyzed by multicolor flow cytometry (Supporting Information
Fig. S11B) in order to confirm the numbers of human CD68+ M1
and M2 macrophages at the wound site. The ratio of human M2
to M1 macrophage marker expressing CD68+ human macro-
phages was increased in wound tissue treated with ABCB5+-
derived MSCs compared with PBS for both the ratio of Dectin-1/
IL-12p40 and CD206/TNFα expressing cells (Fig. 7C). Even though
the humanized model is highly valuable, we cannot fully exclude
that the behavior of still existing murine macrophages will be
changed by the injection of ABCB5+ MSCs, and in consequence,
may affect human cells. These data indicate that the beneficial
anti-inflammatory effect of IL-1RA released from ABCB5+-derived
MSCs on human wound macrophages was conserved in human-
ized NSG mice.
DISCUSSION
We here report that a newly defined dermal cell subpopulation
of the skin with MSC characteristics can be successfully isolated
from its endogenous niche by a single marker, the P-glycoprotein
ABCB5, at high purity and homogeneity. The isolated ABCB5+
MSC subpopulation reliably maintains the capacity of clonal self-
renewal and clonal trilineage differentiation in vitro. Our major,
previously unreported, finding is that injection of the newly
described ABCB5+ lineage-derived MSCs around wounds—via
paracrine IL-1RA release—switch proinflammatory M1 macro-
phages with unrestrained activation to anti-inflammatory wound
repair-promoting M2 macrophages in chronic iron-overload wounds
and, in consequence, accelerate impaired wound healing in vivo
(Graphical Abstract). This constitutes a major preclinical
breakthrough at the forefront of MSC-based therapies in transla-
tional medicine that—due to the lack of an appropriate selection
marker—so far suffered from therapeutic application of less
characterized MSC populations with inconsistent efficacy and
potency [27].
The advancement of isolating and expanding MSCs from the
skin to high homogeneity depends on the exclusive expression of
ABCB5 on MSCs but not on other cells in the skin. Employing a
global transcriptomic approach, we here confirmed the existence
of dermal ABCB5+ cells with a MSC characteristic cell surface
expression profile [1, 24] and reported coexpression with addi-
tional pluripotency and stem cell markers (10–13). We also pro-
vide evidence from RNA sequence analysis that ABCB5+-enriched
MSCs—even when expanded in culture to high passage
numbers—keep at least in part their stemness, MSC, and mesen-
chymal marker expression of endogenous ABCB5+ cells in the
skin. It is, however, unclear whether endogenous ABCB5+ MSCs
and derivatives thereof have a relationship to previously charac-
terized fibroblast lineages [28, 29]. In fact, we found expression
of some upper lineage markers of platelet-derived growth factor
alpha (PDGFα) fibroblast lineage tracing mice [28] in ABCB5+-
derived MSCs, like Prdm1/Blimp-1, a maturation marker for B lym-
phocytes, and CD26/Dpp4, a dipeptidyl peptidase that cleaves
dipeptides from peptides such as growth factors, chemokines,
neuropeptides, and vasoactive peptides,We did not find, however,
coexpression of ABCB5+ cells and α-SMA+, a lower scar-promoting
fibroblast lineage marker in the skin [28]. These data suggest
that the herein used ABCB5+-derived MSCs may share some
expression features of scar-reducing upper lineage fibroblasts.
As to their expression profile, a relationship of ABCB5+-derived
MSCs to Engrailed-1-derived fibroblast lineages cannot be
excluded [29].
Independent of the exact relationship to fibroblast line-
ages, our major intent was to employ ABCB5 as a single
marker for the enrichment of MSCs from skin, to exploit this
for MSC-based therapies in difficult-to-treat wounds.
An impressive rescue of impaired wound healing in virtually
all studied phases of iron-overload wounds, indeed, depends on
enhanced IL-1RA release from injected ABCB5+-derived MSCs,
which actively shifted prevailing unfavorable M1 macrophages to
wound healing-promoting M2 macrophages. This finding is of
particular clinical interest given the shared pathogenic role of
unrestrained activation of proinflammatory M1 macrophages,
causing impaired wound healing in difficult-to-treat chronic
wounds in humans [7, 8, 30]. Several lines of evidence support
our finding. First, injection of ABCB5+-derived MSCs, but not of
ABCB5-depleted dermal cells, resulted in enhanced repair of
impaired wound healing in iron-overload mice. Within the wound
bed of iron-overload mice, M2 macrophages were more abun-
dant after ABCB5+-derived MSCs injection in contrast to persisting
high numbers of overactivated M1 macrophages as found in iron-
overload wounds after injection of either PBS or ABCB5-depleted
dermal cell fractions. Second, the occurrence of M2 macrophages
in wound beds of ABCB5+-derived MSC-injected iron-overload
wounds was associated with an increase of anti-inflammatory
IL-10, a typical M2 cytokine that suppresses inflammation. At the
same time, a decrease of the classical M1 macrophage cytokines
TNFα, IL-1, IL-12, and IL-23 only important during early wound
healing phases in recruiting and activating microbiocidal M1 mac-
rophages [31] was observed. Third, our previous data showed
that under M1 macrophage depleting conditions, iron-overload
©2019 The Authors. STEM CELLS published by
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wounds depicted a fully restored switch to M2 macrophages
with improved wound healing similar to non-iron-overload
wounds [7].
As to the question why IL-1RA—apart from IL-1 β—can sig-
nificantly reduce TNFα also, the following scenario is most likely.
Both TNFα and to a higher extent IL-1β concentrations are
Figure 7. ABCB5+-derived MSCs stimulate a shift from human M1 macrophages to M2 macrophages in the humanized NOD-scid IL2rγnull
(NSG) model. (A): Treatment of NSG mouse wounds with ABCB5+ MSCs led to a significantly reduced wound size compared with control
groups at day 5 and day 8. (B): Representative microphotographs of day 5 wounds in humanized NSG mice show human CD68+ macrophages
(green) in the wound bed with increased numbers of human inflammatory TNFα+ (red) macrophages in PBS-treated wounds compared with
ABCB5+-derived MSC treatment (left panel). Coimmunostaining with M2 marker CD206 (red) displays an MSC-dependent increase in iron-
overload wounds (right panel). Nuclei are counterstained with DAPI (blue). Scale bars = 50 μm. (C): Flow cytometry analysis of human
CD68+-gated macrophages confirmed the ABCB5+ MSC-dependent phenotype shift from M1 to M2 with two different costainings. The ratios
of both Dectin-1+/IL-12p40+ human macrophages and CD206+/TNFα+ increased after treatment with ABCB5+ MSCs. ns = not significant;
*, p < .05; **, p < .01, t test. Abbreviations: ABCB5, ATP-binding cassette subfamily B member 5; DAPI, 40,6-diamidino-2-phenylindole; HDF,
human dermal fibroblasts; IL, interleukin; MSC, mesenchymal stem cells; PBS, phosphate-buffered saline; TNFα, tumor necrosis factor alpha.
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increased in the iron-overload murine wound model, both cyto-
kines driving activation of inflammatory cells, particularly macro-
phages. Both IL-1β and TNFα can activate NFκB [32, 33], which
itself transactivates target genes such as IL-1β, IL-6, and TNFα
among other proinflammatory cytokine and chemokine. In con-
sequence, if IL-1RA neutralizes the high amounts of IL-1β, we
expect that the vicious cycle of NFκB activation is significantly
reduced with overall less activation and expression of target
genes such as IL-1β and TNFα. As IL-1β predominantly enforces
its effect via IL-6 induction [32, 34], IL-1RA most likely would
impact on overall IL-6 concentrations, and consequently on NFκB
activation and downstream target genes. Certainly, we cannot
exclude other driver cytokines beyond IL-1β and TNFα. What we
though can conclude from our data is that IL-1RA released from
ABCB5+ MSCs does play a causal role in rebalancing the hostile
microenvironment of chronic iron-overload wounds.
It is likely that the inflammasome, a multiprotein complex, is
responsible for the enhanced release of IL-1β in our iron-
overload wound model. In fact, both iron and constituents of
bacteria contaminating chronic wounds promote inflammasome
overactivation [35, 36]. The role of the inflammasome in acute
and chronic tissue damage is complex and far from being fully
understood. Transient activation of the inflammasome during
physiological wound healing is a prerequisite to coordinate the
inflammatory response in defense against microbial invasion and
to effectively remove tissue debris [36]. The inflammasome-
dependent maturation of IL-1β occurs via cleavage of the pro-
peptide through caspase 1 and is necessary to recruit and
activate neutrophils and macrophages to the site of injury.
Inhibition of this inflammasome-dependent maturation step
of IL-1β in mice deficient for caspase 1 revealed delayed
wound healing [37]. Unrestrained activation of IL-1β in mice
deficient of the IL-1RA resulted in a fibrotic response of lung
tissue in a model of chlamydia pneumonia infection [38]. Simi-
lar to our data, persistent inflammasome-dependent activa-
tion of IL-1β in diabetic mice also correlates with delayed
wound healing of skin wounds [39], which can be almost
completely restored to normal healing by suppression of the
inflammasome [40]. Our findings in conjunction with the above
reports show that balanced inflammasome activation is crucial
for coordinated tissue repair, and if this balance is disrupted,
wound healing will be impaired.
Descriptive evidence that MSCs dampen single aspects of
macrophage activation in vitro [16, 17, 41–43] and even in
acute wound models has been reported [16, 17, 43, 44]. How-
ever, a thorough characterization of the switch from M1 to M2
macrophages or the responsible paracrine mechanism is lac-
king. Therefore, the present approach highlights the usefulness
of a more complete assessment of the paracrine effects of
ABCB5+-derived MSCs on healing of chronic wounds and hel-
ped to identify IL-1RA as the key effector molecule responsible
for a rigorous switch from proinflammatory, detrimental M1
macrophages to anti-inflammatory M2 macrophages.
Our data on the paracrine effect of IL-1RA released from
ABCB5+-derived MSCs are in line with previous findings [45]. In this
regard, IL-1RA knockout mice displayed delayed wound healing of
acute wounds [45]. Furthermore, improved healing was reported
in mice with a targeted deletion of the IL-1 receptor (IL-1R) or after
treatment with recombinant IL-1RA of acute wounds of wild-type
mice [46] and of diabetic mice [8]. IL-1RA secretion from less well-
characterized MSCs has been described to be beneficial in a variety
of pathological conditions in preclinical studies [47]. We here
distinctly advance our understanding that the shift from the
unrestrained proinflammatory M1 to the anti-inflammatory M2
macrophages is due to the beneficial IL-1RA effects reliably con-
trolling macrophage-dominated tissue inflammation.
In line with our concept and data, there is clear evidence
from the literature [48] that human IL-1RA can efficiently bind
to murine cells with a high affinity and thereby inhibit murine
IL-1β binding and signaling. In this regard, human IL-1RA has
earlier been shown to bind to the type I IL-1 receptor on
murine cells with an affinity of 150 pM, equal to the binding
of human IL-1α and IL-1β.
Our findings cannot exclude that, in addition to IL1RA, other
mechanisms may contribute to counteract tissue damage because
of the unrestrained M1 macrophage activation. In fact, several
investigators including ourselves have earlier shown that MSCs
dampen inflammation and, in consequence, reduce scar formation
in tissue repair via the release of TSG-6 [17, 49]. By contrast to
accelerated healing of full-thickness wounds following TSG-6
release from MSCs injected at the wound site [17], although
TSG-6 was expressed at the wound site of iron-overload wounds,
TSG-6 apparently does not play a major role in accelerating
healing of iron-overload wounds. In fact, injection of recombi-
nant TSG-6 at concentrations that enhance acute wound healing
does not enhance healing of iron-overload wounds. Differences
in the microenvironment will be sensed by injected MSCs,
which, in consequence, may raise different adaptive responses
in terms of the anti-inflammatory factors released.
Apart from IL-1RA, other factors may contribute to the
accelerated healing. In this regard, MSCs have been reported
to suppress oxidative damage during sepsis via PGE2-dependent
reprogramming of macrophages to increase the release of anti-
inflammatory IL-10 [50]. In addition, by enhanced IL-6 and TGF-β
release, MSCs inhibit neutrophil recruitment by cytokine-
activated endothelial cells [51].
A minor limitation of the murine wound model used is the
modest delay in wound closure compared with nonhealing CVU
in patients. Nevertheless, this model mimics the iron-induced
unrestrained activation of wound M1 macrophages with pro-
longed inflammation and tissue breakdown and, hence, repre-
sents a well-suited model to study the effect of treatment
strategies on these specific pathophysiological traits [7].
CONCLUSION
In aggregate, our findings have substantial clinical impact for
the planned implementation into clinical routine. Here, we first
uncovered the adaptive release of a key factor efficiently damp-
ening unrestrained M1 macrophage-dominated inflammation
underlying dysregulated tissue repair in iron-overload chronic
wounds. Second, the employment of a single marker strategy
allows the enrichment of an easily accessible homogeneous
ABCB5+-derived MSC population from human skin with GMP
grade quality, ready to use for transition into clinics. Third, we
developed an in vitro assay predictive for the successful action of
the used MSC preparations in a chronic murine wound model.
ABCB5+-derived MSC preparations from different donors, alone
or pooled, successfully suppressed the release of M1 macro-
phage cytokines, and this suppressive effect correlated well with
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the improvement of healing when the corresponding ABCB5+-
derived MSCs were injected into iron-overload wounds.
Thus, the above data reveal enhanced efficacy and potency
of the newly described dermal ABCB5+-derived MSCs, which
hold substantial promise for the successful clinical therapy of
nonhealing wounds. In fact, clinical phase IIa studies have
recently been initiated (EudraCT number: 2015-000399-81, 2017-
000233-31, 000234-57) with promising results of the first studied
patients.
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